Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter

IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

See all formats and pricing
More options …
Volume 57, Issue 6


Evaluation of analytical performances using standardized analytical protocols and comparison of clinical results of the new ADVIA BNP and NT-proBNP immunoassays for the Centaur XPT platform

Silvia Masotti / Veronica Musetti / Concetta Prontera / Simona Storti / Rudina Ndreu / Claudio Passino / Giancarlo Zucchelli / Aldo Clerico
  • Corresponding author
  • Scuola, Superiore Sant’Anna, Department of Laboratory Medicine, Fondazione G. Monasterio CNR – Regione Toscana, Via Giuseppe Moruzzi 1, 56124 Pisa, Italy
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2018-11-09 | DOI: https://doi.org/10.1515/cclm-2018-0760



The study aim was to evaluate and compare analytical performances and clinical results of ADVIA BNP and PBNP methods using the Centaur XPT platform with those of Access BNP, using the DxI platform and the ECLIA NT-proBNP method, using the Cobas e411 platform, respectively.


Limits of blank (LoB), detection (LoD) and quantitation (LoQ) at 20% CV and 10% CV were evaluated according to international standardized protocols. The analytical parameters were assessed throughout a 90-working-day period using three curve calibrations.


LoB, LoD and LoQ at 20% CV and 10% values of the ADVIA BNP method were 1.0 ng/L, 2.0 ng/L, 3.7 ng/L and 10.2 ng/L, respectively; while those of the ADVIA PBNP method were 1.3 ng/L, 3.0 ng/L, 9.7 ng/L and 22.3 ng/L, respectively. The ADVIA BNP and PBNP methods were able to measure the clinical decision values suggested by international guidelines for diagnosis of heart failure (HF) with an imprecision ≤6%. BNP concentrations measured with the ADVIA and Access methods showed a close linear regression (R=0.9923, n=200); a close linear regression was also found between NT-proBNP concentrations measured with the ADVIA and ECLIA methods (R=0.9954, n=202). However, the ADVIA method measured significantly lower BNP values than the Access method (on average −20.9%), while ADVIA PBNP method measured significantly higher NT-proBNP concentrations than the ECLIA method (on average +17.8%).


Analytical performances of the BNP and PBNP ADVIA methods are well in accordance with the quality specifications required by international guidelines for diagnosis and follow-up of patients with HF.

This article offers supplementary material which is provided at the end of the article.

Keywords: cardiac endocrine function; cardiovascular risk; heart failure; immunoassay methods; natriuretic peptides


  • 1.

    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2013;128:e240–327.Web of ScienceGoogle Scholar

  • 2.

    Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.Web of ScienceGoogle Scholar

  • 3.

    Clerico A, Fontana, M, Ripoli A, Emdin M. Clinical relevance of BNP measurement in the follow-up of patients with chronic heart failure. Adv Clin Chem 2009;48:163–79.CrossrefWeb of SciencePubMedGoogle Scholar

  • 4.

    Passino C, Barison A, Vergaro G, Gabutti A, Borrelli C, Emdin M, et al. Markers of fibrosis, inflammation, and remodeling pathways in heart failure. Clin Chim Acta 2015;443:29–38.Web of SciencePubMedCrossrefGoogle Scholar

  • 5.

    Clerico A, Passino C, Franzini M, Emdin M. Cardiac biomarker testing in the clinical laboratory: where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. Clin Chim Acta 2015;443:17–24.Web of SciencePubMedCrossrefGoogle Scholar

  • 6.

    Clerico A, Zaninotto M, Passino C, Plebani M. New issue on measurement of B-type natriuretic peptides. Clin Chem Lab Med 2017;56:32–9.Google Scholar

  • 7.

    Richards AM, Troughton EW. Use of natriuretic peptides to guide and monitor heart failure therapy. Clin Chem 2012;58:62–71.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 8.

    Januzzi JL, Troughton R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. Circulation 2013;127:500–7.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 9.

    Troughton R, Michael Felker G, Januzzi JL Jr. Natriuretic peptide-guided heart failure management. Eur Heart J 2014;35:16–24.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 10.

    Clerico A, Giannoni A, Vittorini S, Passino C. Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol 2011;301:H12–20.CrossrefPubMedGoogle Scholar

  • 11.

    Seferian KR, Tamm NN, Semenov AG, Mukharyamova KS, Tolstaya AA, Koshkina EV, et al. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem 2007;53:866–73.Web of ScienceCrossrefPubMedGoogle Scholar

  • 12.

    Shimizu H, Masuta K, Aono K, Asada H, Sasakura K, Tamaki M, et al. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 2002;316:129–35.CrossrefPubMedGoogle Scholar

  • 13.

    Shimizu H, Masuta K, Asada H, Sugita K, Sairenji T. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta 2003;334:233–9.CrossrefPubMedGoogle Scholar

  • 14.

    Liang F, O’Rear J, Schellenberger U, Tai L, Tai L, Lasecki M, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007;49:1071–8.Web of ScienceCrossrefPubMedGoogle Scholar

  • 15.

    Hammerer-Lercher A, Halfinger B, Sarg B, Mair J, Puschendorf B, Griesmacher A, et al. Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure. Clin Chem 2008;54:858–65.Web of SciencePubMedCrossrefGoogle Scholar

  • 16.

    Prontera C, Zaninotto M, Giovannini S, Zucchelli GC, Pilo A, Sciacovelli L, et al. Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the CardioOrmoCheck study. Clin Chem Lab Med 2009;47:762–8.PubMedWeb of ScienceGoogle Scholar

  • 17.

    Clerico A, Zaninotto M, Prontera C, Giovannini S, Ndreu R, Franzini M, et al. Study Group on Cardiovascular Risk Biomarkers of the Italian Society of Clinical Biochemistry. State of the art of BNP and NT-proBNP immunoassays: the CardioOrmoCheck study. Clin Chim Acta 2012;414:112–9.CrossrefGoogle Scholar

  • 18.

    Rawlins ML, Owen WE, Roberts WL. Performance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol 2005;123:439–45.CrossrefPubMedGoogle Scholar

  • 19.

    Prontera C, Zucchelli GC, Vittorini S, Storti S, Emdin M, Clerico A. Comparison between analytical performances of polyclonal and monoclonal electrochemiluminescence immunoassays for NT-proBNP. Clin Chim Acta 2009; 400:70–3.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 20.

    Prontera C, Storti S, Emdin M, Passino C, Zyw L, Zucchelli GC, et al. Comparison of a fully automated immunoassay with a point-of-care testing method for B-type natriuretic petide. Clin Chem 2005;51:1274–6.CrossrefGoogle Scholar

  • 21.

    Currie LA. Nomenclature in evaluation of analytical methods including detection and quantitation capabilities. Pure Appl Chem 1995;67:1699–723.CrossrefGoogle Scholar

  • 22.

    BS ISO 11843-1:1997. Capability of detection – part 1: terms and definitions. Incorporating corrigenda July 2000 and November 2003 by British Standard Institution. International Standards Organisation, Geneva, 1997 and British Standard Institution, November 2003.Google Scholar

  • 23.

    CLSI EP17-A protocol. Protocols for determination of limits of detection and limits of quantitation; approved guidelines. 2004, Vol. 24, No. 34. Wayne, PA.Google Scholar

  • 24.

    CLSI EP5-A2 protocol. Evaluation of precision performance of quantitative measurement methods; Approved guideline – Second edition. 2004, Vol. 24, No. 25. Wayne, PA.Google Scholar

  • 25.

    Huber PJ, Ronchetti EM. Robust statistics, 2nd ed. New Jersey: John Wiley & Sons, Inc. Hoken, NJ, 2009.Google Scholar

About the article

Corresponding author: Prof. Aldo Clerico, MD, Scuola, Superiore Sant’Anna, Department of Laboratory Medicine, Fondazione G. Monasterio CNR – Regione Toscana, Via Giuseppe Moruzzi 1, 56124 Pisa, Italy, Phone: +39-0585-493569, Fax: +39-0585-493652

Received: 2018-07-19

Accepted: 2018-10-02

Published Online: 2018-11-09

Published in Print: 2019-05-27

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 57, Issue 6, Pages 911–917, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2018-0760.

Export Citation

©2019 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Supplementary Article Materials

Comments (0)

Please log in or register to comment.
Log in